The carbohydrate response element-binding protein (ChREBP), also referred to as 
(SNPs) in or near the ChREBP gene have been found to be associated with plasma triglyceride levels by genome-wide association studies (GWASs). [8] [9] [10] During the last decade, more than 20 studies confirmed the association between ChREBP gene variations and plasma triglyceride levels, as well as the association with coronary artery disease (CAD). [11] [12] [13] [14] [15] [16] MicroRNAs (miRNAs) are small non-coding RNAs (19-22 nucleo- tides) known to be regulators of gene expression at post-transcriptional levels. 17 The previous studies have shown that miRNAs could alter gene expression and individual susceptibility to disease traits, and variants located in these miRNA binding sites may alter clinical characteristics and disease susceptibility. [18] [19] [20] To our knowledge, whether polymorphism in the 3′-UTR of ChREBP could modify gene expression and further influence triglycerides and glucose levels has not been clearly demonstrated. Therefore, we performed a bioinformatics analysis to identify the potential functional variant in the 3′-UTR of ChREBP. As a result, the known polymorphism, rs1051943, was found in the seed binding site of miR-1322, one of the 69 miRNAs previously identified to be associated with abnormal lipid levels. 21 Based on these results, we hypothesized that the human rs1051943 polymorphism could regulate ChREBP expression by influencing miR-1322 binding and thus affect plasma levels of lipids and glucose.
| MATERIALS AND METHODS

| Bioinformatics analysis
Bioinformatics analysis was performed with three distinct software tools. miRanda (http://www.microrna.org/), RegRNA (http://www.lnc rnablog.com/) and miRTarBase (http://mirtarbase.mbc.nctu.edu.tw/)
were used to predict miRNA binding sites in 3′-UTR of ChREBP. The results were then confirmed by TargetScan 7.1 (http://www.targe tscan.org/). With data from Asia, Europe, Africa and China, the 1000
Genomes Project (http://www.hapmap.org/, phase3) provided the SNPs in 3′-UTR of ChREBP and the minor allele frequency (MAF), which was greater than 0.01.
| Luciferase assay
The 671-bp ChREBP 3′-UTR sequence flanking rs1051943 containing a wild-type allele (rs1051943-A) was amplified from human DNA by polymerase chain reaction (PCR), with Mlu1 or HindIII restriction enzyme cutting site at 5′ and 3′ end, respectively. PCR products were then digested and inserted into a pMIR luciferase reporter vector (Beijing AuGCT Biotechnology Co., Ltd, China). A mutated vector containing ChREBP 3′-UTR sequence was generated by overlap PCR using primers carrying mutated alleles (forward primer: 5′-TCCTGGCCAGACCCTGCT-3′, reverse primer: 5′-AACCAGCAGA-CAGTTTTTGC -3′). HEK293T and HepG2 cells (1 × 10^6 cells per well) in 24-well plates were co-transfected with 400 ng of pMIR-A (rs1051943-A) or pMIR-G (rs1051943-G) plasmid, 50 ng of Renilla luciferase plasmid, 100 nmol of miR-1322 mimics or mimics negative control (RIBOBIO Co., Ltd, Guangzhou, China) and 200 nmol of miR-1322 inhibitor or inhibitor negative control (RIBOBIO Co., Ltd, Guangzhou, China), using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cy3-labelled transfection control (RIBOBIO Co., Ltd, Guangzhou, China) was used to detect the infection efficiency, as shown in Figure S1 . The sequences of miRNA-1322 mimics and inhibitors are shown in Table S1 . Cells were incubated at 37°C and 5% CO 2 . After 48 hours, the cells were washed using cold phosphatebuffered saline (PBS) and lysed with passive lysis buffer (Promega, WI, USA). Luciferase activities were then measured by a luminometer (SIRIUS, Pforzheim, Germany) according to the manufacturer's instructions. Luciferase expression levels were adjusted with reference to Renilla luciferase activity. Six independent experiments were performed for each reporter vector. Mouse ChREBP 3′-UTR was constructed into the pMIR-Report vector using the above-mentioned procedure (forward primer: 5′-TCCTGGTGAAAGTTTCCAAGC-3′, reverse primer: 5′-CCCAAGTACTGGGATTAAAGGTG-3′). Vectors were then co-transfected with hsa-miR-1322 mimic (100 nmol/L) or mimic negative control (100 nmol/L) in HEK293T cells.
| Recruitment for hypertriglyceride (HTG) patients and control participants
The sequencing cohort included 169 HTG individuals and 313 con- (Table S2 ).
The Institutional Review Board at Tongji Hospital approved this study. Written informed consent was obtained from all three participants. Genetic experiments were conducted according to the principles expressed in the Declaration of Helsinki.
| Genetic variation screening
In order to identify existing variants in the ChREBP gene, Sanger sequencing was performed. Details on sample sequencing were ZHANG ET AL.
| 5323 described in our previous report. 20 Briefly, PCR fragments covering the 3′-UTR of ChREBP (ChREBP consensus sequence, NC_000007.13, GRCh37.p13) were generated using primers (for- After transfection for 24 hours, cell lysates were extracted as described previously. 20 Triglyceride and total cholesterol levels were determined using a commercial assay kit (Nanjing Jiancheng Bioengineering Institute, China) normalized to protein concentration following the manufacturer's instructions. The assay sensitivity was 0.01 mmol/mL, and average intra-and inter-assay coefficients of variation were 3% and 5%, respectively. The absorbance was measured using a BioStack Microplate Stacker (BioTek, WI, USA) according to the instruction manual.
| Triglycerides and total cholesterol assays
| Quantitative real-time PCR
Total RNA was extracted from human normal tissues including liver, adipose tissue, large intestine, small intestine, heart, lung and cell Table S3 .
| Vector construction and miRNA sequencing
cDNA from C57BL/6J mouse liver was amplified using hsa-miR-1322-specific primers (RIBOBIO Co., Ltd, Guangzhou, China). PCR products were then TA-cloned into pMD 19-T vector (Code No. 6013) following the manufacturer's instructions (TakaraBio, Otsu, Japan). Positive clones were selected and sequenced using universal primers. The 
| Bioinformatics analysis of ChREBP 3′-UTR
Bioinformatics analysis demonstrated that 30 miRNAs might contain binding sites in 3′-UTR of ChREBP (Table S4 ) in which 13 miRNAs are confirmed by TargetScan 7.1 as shown in Table 2 . Among these miRNAs, only miR-1322 was found to be associated with abnormal lipid levels. 21 The variant rs1051943 is an A to G change (mRNA sequence as reference), and computer alignment demonstrated that this SNP was located in the miR-1322 binding site in ChREBP 3′-UTR ( Figure 1A ).
| Effects of polymorphisms on activity of ChREBP 3′-UTR in vitro
In HepG2 cells, the luciferase reporter activity of the pMIR-G vector (containing G allele of rs1051943) is significantly increased (58.1 ± 7.3%, P < 0.0001) when compared with the pMIR-A construct (containing A allele of rs1051943) as shown in Figure 1B 
| The effects of miR-1322 on insulin resistance
To further explore the association between miR-1322 and the metabolism of lipids and glucose, cell models for insulin resistance were induced with palmitate or high glucose cell culture media. miR-1322 levels are significantly increased after high glucose ( Figure 4A ) or palmitate stimulation ( Figure 4B ). Although the cell viability was obviously decreased after PA (1.0 mmol/L) treatment ( Figure S4 ), the expression of miR-1322 was positively correlated with the concentration of PA stimulation. In addition, we found that miR-1322 was more highly expressed in HepG2 cells ( Figure 4D ) compared with other cell lines, and an abundant amount of miR-1322 was also detected in the intestine ( Figure 4C ), indicating that miR-1322 could affect insulin resistance.
| Re-sequencing results of 3′-UTR in ChREBP
A total of 482 Han Chinese participants were enrolled, including 169 HTG patients and 313 control participants (Table 1) . Cumulatively, we identified two DNA variants in this population. Of the two variants, one was a common polymorphism (minor allele frequency >1%); the other was a rare polymorphism. No significant differences of genotype frequencies were discovered between the two groups (Table 3) . We did not find significant associations between rs1051921 polymorphism and TG, TC, LDL-C or HDL-C (Table S5 ).
According to the luciferase assay, significant differences of rs1051921-C allele and T allele luciferase activity were discovered ( Figure S5 ). However, no transcription factor or miRNA was predicted in this SNP. Only rs1051943-A allele was found in both control and HTG patients. To eliminate racial differences, 96 Chinese Uighur ethnic participants were also included in the sequencing cohort, of which similar results were found (Table 3) .
| Conservation of 3′-UTR in ChREBP in different species
Sequence alignment showed that 3′-UTR in ChREBP flanking the miR-1322 binding site was conserved in mice and rat ( Figure 5A ).
However, the homology allele of the rs1051943 was a T allele in both species, which could lead to the destruction of the miR-1322 binding site. According to the existing database, the hsa-miR-1322 homologue was not found in both mice and rat. Therefore, we performed bioinformatics analysis with UCSC (http://genome.ucsc.edu/).
The sequence of hsa-miR-1322 was found in chromosome 19 (GRCm38.p4, 29842645 to 29842663) ( Figure 5B ). Liver cDNA of F) . Columns, mean of three independent experiments; error bars, SEM. Results were means of triplicate experiments with at least six replicates. P < 0.05 (*), P < 0.01(**), P < 0.001 (***), P < 0.0001 (****), NS (no significance) mice was amplified using hsa-miR-1322 qPCR primers, and PCR products were then TA-cloned into pMD 19-T vector. Subsequent sequencing of the TA clone conformed to the same sequence of hsa-miR-1322 ( Figure 5C ), indicating the existence of a hsa-miR-1322 homologue in mice ( Figure 5D ). Luciferase activities of the mice 3′-UTR in pMIR-Report construct showed no significant difference after hsa-miR-1322 intervention in 293T cells ( Figure 5E ).
| DISCUSSION
In this study, we identified a functional variant, the A allele of It is clear that ChREBP plays important roles in modulating the process of glycolysis and lipogenesis. 23 Iizuka et al reported that the ChREBP knockout mice showed reduced glycolysis and lipogenesis and exhibited insulin resistance, 24 whereas Benhamed et al showed that the ob/ob mice with ChREBP deletion exhibited reduced lipogenesis and improved insulin sensitivity. These controversial results in different mice models were confirmed by multiple laboratories. 25, 26 Recently, an American obese adolescents study revealed that the expression of ChREBP was significantly increased in the liver with high insulin resistance, which was in contrast to that in adipose tissue. 27 Regarding the aforementioned evidence, ChREBP mechanisms in glucose and lipid metabolism warrant further exploration.
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